Twist Bioscience ( (TWST) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Twist Bioscience is surging after Barclays sharply lifted its price target to $95 from $65 while reiterating an Overweight rating, signaling increased confidence in the company’s prospects. The move follows recent analyst upgrades that spotlight Twist’s leadership in AI-driven drug discovery and its silicon-based DNA synthesis platform, as well as momentum from a second-quarter revenue beat and upbeat long-term guidance shared at Investor Day.
For long-term investors, Twist’s consistent revenue growth, improving margins, and strategic partnerships suggest the business is steadily scaling and its technology is gaining broader adoption, which can eventually support a path to profitability. However, the company still burns cash and remains unprofitable, and its exposure to volatile research budgets and uneven partner demand means execution must stay tight or future results and funding options could come under pressure.
More about Twist Bioscience
YTD Price Performance: 187.99%
Average Trading Volume: 1,607,136
Technical Sentiment Signal: Buy
Current Market Cap: $5.29B
For further insights into TWST stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.


